Clinical Trial Update: A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) [Phase 3]

View source ↗

Summary

A Phase 3 pediatric allergic asthma trial (HAS3) evaluating a histamine pharmacodynamic biomarker to guide treatment is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Snippet

Sponsor: Bridgette Jones | Conditions: Allergic Asthma | Phase 3 | Status: RECRUITING